文献速递血栓与止血

使用血栓弹力图和Khorana评分评估接受化疗的女性癌症患者的高凝状态与静脉血栓栓塞风险

Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy.
PubMed 文献 · Am J Hematol · 2024-02-29

研究纳入36例接受化疗的女性癌症患者(18例乳腺癌、11例子宫内膜癌、7例卵巢癌),用血栓弹力图评估高凝状态并随访6个月静脉血栓栓塞事件。化疗第1周期后63%、第2周期后75%的患者检出高凝状态,MA和CI显著升高,R、K、LY30降低。Khorana评分仅7%为高危、23%为低危、70%为中危;5例发生静脉血栓栓塞,其中受检者100%在化疗第1或第2周期后呈高凝状态,80%为Khorana评分中危。

要点

  • 化疗第1周期后63%、第2周期后75%的女性癌症患者血栓弹力图检出高凝状态。
  • Khorana评分中危和高危患者MA、CI较低危患者显著升高,MA与Khorana评分正相关。
  • 5例发生静脉血栓栓塞,受检者100%在化疗第1或第2周期后呈高凝状态,80%为Khorana评分中危。

核心结论

  • 血栓弹力图是高凝状态的标志物,血栓弹力图-MA和CI可能用于评估静脉血栓栓塞风险。
  • 需要更大规模的研究评估血栓弹力图作为Khorana评分辅助手段以更好预测特定女性癌症静脉血栓栓塞的效用。

研究设计与样本

  • 招募计划接受化疗的癌症患者,记录基线人口学、癌症数据、BMI、Khorana评分和静脉血栓栓塞危险因素,随访6个月观察血栓事件。
  • 共评估36例年龄35-85岁的患者,包括18例乳腺癌、11例子宫内膜癌、7例卵巢癌。

主要发现

  • 化疗第1周期后63%的患者检出高凝状态,第2周期后75%检出,MA和CI显著升高,R、K和LY30降低。
  • Khorana评分显示7%的患者为高危、23%为低危、70%为中危。
  • Khorana评分中危和高危患者与低危患者相比MA和CI显著升高,MA与Khorana评分呈正相关。
  • 5例患者发生实际静脉血栓栓塞,其中受检者100%在化疗第1或第2周期后呈高凝状态,80%为Khorana评分中危。

局限性

  • 原文指出当前Khorana评分及其修改版在女性癌症中存在局限性。
  • 原文结论提出需要更大规模的研究评估血栓弹力图作为Khorana评分辅助手段的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a common occurrence in cancer and chemotherapy increases thrombosis risk. Current risk assessment models such as the Khorana score (KS) and its modifications have limitations in female cancers. We assessed the coagulation profile of a group of women cancer patients under chemotherapy using thromboelastography (TEG) to determine if this can inform VTE risk assessment. Cancer patients who planned to receive chemotherapy were recruited. Baseline demographics, cancer data, BMI, Khorana Score (KS), and VTE risk factors were recorded and patients were followed for 6 months, for any thrombotic events. A total of 36 patients aged 35-85 (18 breast, 11 endometrial, 7 ovarian cancer) were evaluated. Hypercoagulability was detected in 63% of patients post-chemo cycle 1 and 75% post-cycle 2, with a significant increase in MA (maximum amplitude) and CI (clotting index), reduction in R (reaction time), K (clot kinetics), and LY30 (lysis time after 30 min of MA). KS showed only 7% of patients were high risk, 23% were low, and 70% were intermediate risk. MA and CI significantly increased in patients with intermediate and high-risk KS when compared with the low-risk patients and MA was positively correlated with KS. Five patients developed actual VTE; 100% of the tested ones were hypercoagulable either post-cycle 1 or 2 and 80% were KS intermediate risk. TEG is a hypercoagulability marker and TEG-MA and CI can potentially assess VTE risk. Larger studies are needed to assess the utility of TEG as an adjuvant to KS to better predict VTE in specific female cancers.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tera Y, Suh YJ, Fainchtein K, et al. Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy. Am J Hematol. 2024. PMID: 38425173. doi:10.1002/ajh.27273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。